NCT05456724View on ClinicalTrials.gov

A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 4, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

July 31, 2024

Conditions
Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

TO-O-1001

TO-O-1001 ophthalmic solution in two concentration (0.05% and 0.1%) ocular administration only one drop in one eye

OTHER

Placebo

The placebo is of same visual appearance and identical formulation as TO-O-1001, except the active component TO-168 ocular administration only one drop in one eye

Trial Locations (1)

3004

Nucleus Network Melbourne, Melbourne

All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Theratocular Biotek Co.

INDUSTRY

NCT05456724 - A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter